Piper Jaffray upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Overweight with a price target of $39, saying diligence supportive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE